Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for Oncology Institute (TOI) over the last 5 years, with Q3 2025 value amounting to $117.6 million.

  • Oncology Institute's Cost of Revenue rose 3753.9% to $117.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.0 million, marking a year-over-year decrease of 3520.73%. This contributed to the annual value of $186.9 million for FY2024, which is 323.89% up from last year.
  • As of Q3 2025, Oncology Institute's Cost of Revenue stood at $117.6 million, which was up 3753.9% from $51.2 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Cost of Revenue registered a high of $117.6 million during Q3 2025, and its lowest value of -$66.9 million during Q4 2024.
  • Over the past 5 years, Oncology Institute's median Cost of Revenue value was $42.8 million (recorded in 2023), while the average stood at $39.2 million.
  • Examining YoY changes over the last 5 years, Oncology Institute's Cost of Revenue showed a top increase of 9024.27% in 2024 and a maximum decrease of 23833.43% in 2024.
  • Oncology Institute's Cost of Revenue (Quarter) stood at $27.4 million in 2021, then surged by 40.34% to $38.4 million in 2022, then rose by 26.01% to $48.4 million in 2023, then plummeted by 238.33% to -$66.9 million in 2024, then skyrocketed by 275.84% to $117.6 million in 2025.
  • Its Cost of Revenue was $117.6 million in Q3 2025, compared to $51.2 million in Q2 2025 and $47.1 million in Q1 2025.